Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains les...
Saved in:
Main Authors: | Andrea Ceglédi (Author), Zoltán Csukly (Author), Mónika Fekete (Author), András Kozma (Author), Zsuzsanna Szemlaky (Author), Hajnalka Andrikovics (Author), Gábor Mikala (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary
by: Szilvia Lovas, et al.
Published: (2022) -
Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement
by: Andrea Ceglédi, et al.
Published: (2023) -
Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol
by: Andrea Ceglédi, et al.
Published: (2024) -
Synergistic effect of venetoclax and teglicar in multiple myeloma cell lines
by: Belal A. Al-Husein, et al.
Published: (2024) -
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
by: Bassali J, et al.
Published: (2020)